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1381First, it is uncertain whether the study was
adequately powered to detect differences in the
heterogeneous CRC patient cohort. Chemotherapy
and targeted therapeutics have well-deﬁned cardiac-
and vascular-speciﬁc molecular and cell-signaling
pathways resulting in alterations in systemic vas-
culature, autonomic dysfunction, and progressive
cardiac damage (3). A closer look at the data pre-
sented by Cramer et al. (1) reveals physiologically
meaningful, although statistically nonsigniﬁcant,
differences between naïve and therapy patients in
systolic blood pressure (w8 mm Hg), peak heart rate
(w18 beats/min), and parasympathetic drive (stan-
dard deviation of normal to normal, w7.8 ms; heart
failure, w41 ms2). Although there were no differ-
ences in resting left ventricular ejection fraction
(LVEF) between groups, the use of novel imaging
techniques such as speckle tracking echocardiogra-
phy (4) and evaluation of cardiac parameters during
exercise stress may provide more sensitive tools for
detecting altered myocardial performance beyond
LVEF.
Second, a respiratory exchange ratio (RER) of $1.10
is typically used to determine peak values, not $1 as
reported. In a cohort of breast cancer patients, it was
found that 22% of patients did not achieve the criteria
for a true peak VO2 (i.e., RER $1.10) (5). It is possible
that using a lower standard for peak may have
resulted in an underestimation of the observed
impairment in cardiopulmonary function in patients
with CRC. We wonder whether there is a difference in
the number of patients who were able to achieve an
RER of $1.10, and if so, whether this alters any pre-
dictors of peak VO2 (Table 5 in Cramer et al. [1]).
Last, although traditional metrics such as peak VO2
provide a measure of the integrative capacity of oxy-
gen cascade components, use of other indexes may
provide distinct but complementary information
regarding potentialmechanisms of exercise limitation.
For example, submaximal parameters (e.g., anaerobic
threshold; VE/VCO2, oxygen uptake efﬁciency slope
[OUES]) could provide particularly valuable diag-
nostic, prognostic, and clinical decision-making in-
formation. Indeed, Cramer et al. (1) found signiﬁcant
differences in VE/VCO2 between naïve and therapy
patients; whether such differences in anaerobic
threshold or OUES exist were not reported.
Clearly, larger studies designed to address the
impact of both the cancer itself and the cancer ther-
apy on determinants of peak VO2 are required. Such
investigations will help provide a deeper under-
standing of oncology-induced cardiac phenotypes,
which, in turn, will provide much needed information
for cardiotoxicity interventions.*Jessica M. Scott, PhD
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Oncol 2012;30:2530–7.REPLY: Cardiovascular Function and Exercise
Capacity in Patients With Colorectal Cancer
Does Anticancer Therapy Matter?Drs. Scott and Haykowsky raise concerns about our
recently published study (1) on cardiovascular alter-
ations in patients with colorectal cancer. In particular,
they question the sample size of our study cohort and
suggestmore sophisticated technology such as speckle
tracking echocardiography as a more sensitive tool for
altered myocardial performance, to use the usual cut-
off value for the respiratory exchange ratio (RER), and
to present additional information regarding potential
mechanisms of exercise limitation.
We agree that our sample size was comparatively
small, but patients were included prospectively in the
cohort that matches well with the control groups with
regard to baseline parameters. We also agree that, as
outlined in our study limitations section, larger
studies are required to better understand the changes
to the cardiovascular system that are induced by the
tumor itself, rather than by chemotherapy. Indeed,
detailed data on this topic are still sparse, and we
believe that this is an area of research that has by far
not received sufﬁcient research endeavor so far. In
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1382particular, we see huge possibilities for future thera-
peutic interventions and thus improvement of car-
diovascular function and, thereby, quality of life in
patients with cancer. With regard to spiroergometry
assessment, a cutoff value for the RER value was
indeed $1.10 in a number of studies, as this sup-
posedly indicates maximal effort and prognostic
sensitivity. This is, however, not the only cutoff used
in previous studies. Although some authors have
used a cutoff >1.05 or >1.00 (2), others have sug-
gested that a cutoff >1.00 or >0.95 could be accept-
able if this represents a change of at least 0.15 over
baseline (3,4). Using data from more than 1,700 pa-
tients with heart failure with reduced ejection frac-
tion, Chase et al. (5) recently reported that both peak
VO2 and VE/VCO2 slope remained signiﬁcant predictors
of major adverse cardiac events in all subgroups of
RER, even in those with an RER <1.00. We, therefore,
strongly believe in the methodology that we applied
in this prospective study of cardiovascular function
and exercise capacity in patients with colorectal
cancer.
Additional analyses are always welcome, but due
to the overwhelming amount of data that our study
produced, we had to limit ourselves to those param-
eters that we considered most important.Larissa Cramer
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427–32.The Importance of the
Cardiac Cycle in the
Imaging Criteria for
Left Ventricular
NoncompactionWe read with great interest the recent review by
Arbustini et al. (1) highlighting the different aspects
of the left ventricular noncompaction (LVNC). In this
paper, the authors review pathophysiology, anatomy,
epidemiology, genetics, and the imaging for diagnosis
and other aspects related to this interesting and not
well known entity. However, 1 limitation of the re-
view, especially regarding the imaging diagnosis with
cardiac magnetic resonance, should be also brought
to the readers’ attention.
The authors stated that for an echocardiography
diagnosis after careful evaluation of all criteria, the
most important echocardiographic criterion remains a
noncompacted/compacted ratio greater than 2.0 in
end-systole, well known as the Jenni criteria (2). One
important detail in this case is that the measurement
must be performed during the end-systolic phase of
the cardiac cycle.
The authors do not provide by the other side a
completely clear criteria for the measurement on CMR
that they consider the technique that conﬁrms diag-
nosis in the central illustration. They mentioned
a noncompacted/compacted ratio greater than 2.3
on CMR be considered the cutoff for an LVNC diag-
nosis (3), the Petersen criteria, but they neglected to
mention when we must perform this measurement,
something of importance due to the different moment
in the cardiac cycle at which it must be performed
compared with echocardiography. The diagnosis with
CMR is suggested when the noncompacted/com-
pacted ratio is greater than 2.3 during end-diastole.
In our opinion, there is a lot of room for improve-
ment in the diagnosis of this entity due to the im-
portant differences that an incorrect measurement
could cause and also whether we need to take into
account a different moment in the cardiac cycle at
which to perform the measurements, depending on
what imaging technique we use for the diagnosis or
even where we must make the measurement (4).
Maybe it is time to add genetics to improve this
